NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









858 Therapeutics

858 Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://8five8tx.com/

Last Round

Series B

Sep 26, 2024

Total Funding Raised

$110M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

858 Therapeutics is a biotechnology company that develops small molecule therapeutics targeting novel oncology and immunology areas, including DNA damage response, innate immunity, and RNA modulation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologysmall molecule therapeuticsoncologyPARG inhibitordrug discoveryRNA modulationDNA damage responseclinical-stage biotechcancer researchvirtual screeningprecision medicinedrug pipelinebiotech startuptherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

858 Therapeutics Comparables

Compare 858 Therapeutics with similar companies based on industry and business-model similarity.

858 Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
FoRx Therapeutics
88%
KSQ Therapeutics
87%
IDEAYA Biosciences, Inc.
81%

858 Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 26, 2024
Series ASep 21, 2021

858 Therapeutics Investors

Notable investors and investment history

858 Therapeutics investors
InvestorRounds
New Enterprise Associates (NEA)Series B, Series A
Cormorant Asset ManagementSeries A
Avidity PartnersSeries B
Logos CapitalSeries B, Series A
Versant VenturesSeries B, Series A
Alexandria Venture InvestmentsSeries B
Mirae Asset CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors increased 35% MoM.

  • May 18, 2026

    Monthly visitors increased 151% MoM.

858 Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

858 Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about 858 Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range21
Year Founded2019
Last FundingSep 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.